Warning Letter — Ketacyn Pharmaceuticals / www.ketacynpharma.com
The FDA issued a Warning Letter to Ketacyn Pharmaceuticals (www.ketacynpharma.com) via the Center for Drug Evaluation and Research regarding regulatory compliance issues.
This affects Ketacyn Pharmaceuticals, as well as regulatory and compliance departments responsible for overseeing pharmaceutical marketing and website content.
The issuance of a Warning Letter by CDER indicates that the company's products or marketing practices have failed to meet federal standards, likely involving the distribution of unapproved or misbranded drugs. For regulatory professionals, this underscores the FDA's ongoing scrutiny of online pharmaceutical sales and the necessity of maintaining rigorous pre-market approval and labeling compliance.
Regulatory and legal teams should audit all digital properties and product listings to ensure no unapproved drug claims are present. Review procedures for internal vetting of marketing materials and website content to prevent the distribution of misbranded or unapproved products.
FDA Warning Letter issued to: Ketacyn Pharmaceuticals / www.ketacynpharma.com. 06/23/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/ketacyn-pharmaceuticals-wwwketacynpharmacom-725153-06232026
Open in openFDA / FDA.gov